Bacterial Vaginosis-Pipeline Review, H2 2015

Bacterial Vaginosis-Pipeline Review, H2 2015

  • Products Id :- GMDHC6907IDB
  • |
  • Pages: 57
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Bacterial Vaginosis-Pipeline Review, H2 2015


Global Markets Direct's, 'Bacterial Vaginosis-Pipeline Review, H2 2015', provides an overview of the Bacterial Vaginosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bacterial Vaginosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bacterial Vaginosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Bacterial Vaginosis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Bacterial Vaginosis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Bacterial Vaginosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Bacterial Vaginosis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Bacterial Vaginosis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Bacterial Vaginosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Bacterial Vaginosis Overview 6

Therapeutics Development 7

Pipeline Products for Bacterial Vaginosis-Overview 7

Pipeline Products for Bacterial Vaginosis-Comparative Analysis 8

Bacterial Vaginosis-Therapeutics under Development by Companies 9

Bacterial Vaginosis-Therapeutics under Investigation by Universities/Institutes 10

Bacterial Vaginosis-Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Bacterial Vaginosis-Products under Development by Companies 14

Bacterial Vaginosis-Products under Investigation by Universities/Institutes 15

Bacterial Vaginosis-Companies Involved in Therapeutics Development 16

Alfa Wassermann S.p.A 16

AmVac AG 17

Osel Inc. 18

Starpharma Holdings Limited 19

Symbiomix Therapeutics, LLC 20

Bacterial Vaginosis-Therapeutics Assessment 21

Assessment by Monotherapy Products 21

Assessment by Target 22

Assessment by Mechanism of Action 23

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Profiles 28

AMV-100-Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

astodrimer-Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

benzoyl peroxide-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

LACTIN-V-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Peptide for Bacterial Vaginosis-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

rifaximin-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

secnidazole-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Bacterial Vaginosis-Recent Pipeline Updates 38

Bacterial Vaginosis-Dormant Projects 45

Bacterial Vaginosis-Discontinued Products 46

Bacterial Vaginosis-Product Development Milestones 47

Featured News & Press Releases 47

Jun 09, 2015: Symbiomix Therapeutics Doses First Patient in Confirmatory Phase 3 Pivotal Study of Lead Drug Candidate SYM-1219 for Bacterial Vaginosis 47

May 05, 2015: Symbiomix Therapeutics Announces Positive Results from a Pivotal Phase 2 Trial of SYM-1219 for the Treatment of Bacterial Vaginosis 47

Mar 04, 2015: Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 48

Nov 21, 2014: SYM-1219 Chosen as one of the Top Infectious Disease Projects to Watch by Therapeutic Area Partnerships 49

Sep 09, 2014: Symbiomix Therapeutics Makes First Corporate Announcement: Completion of Enrollment in a Phase 2 Clinical Trial of SYM-1219 for Bacterial Vaginosis 49

Jul 14, 2014: FDA Grants SPA Agreement for Phase 3 Recurrent BV Trial 50

May 17, 2014: Phase 2 Clinical Trial Investigator Meeting Held in Dallas, Texas, May 17, 2014 51

Apr 03, 2013: Starpharma Announces Positive Results From Phase II Study Of VivaGel For Prevention Of Recurrent Bacterial Vaginosis 51

Nov 28, 2012: Starpharma Announces Results From Two Phase III Studies Of VivaGel For Treatment Of Bacterial Vaginosis 53

Oct 18, 2012: Starpharma Completes Recruitment In Two Phase III Trials Of VivaGel For Treatment For Bacterial Vaginosis 54

Appendix 56

Methodology 56

Coverage 56

Secondary Research 56

Primary Research 56

Expert Panel Validation 56

Contact Us 56

Disclaimer 57

List of Tables

Number of Products under Development for Bacterial Vaginosis, H2 2015 7

Number of Products under Development for Bacterial Vaginosis-Comparative Analysis, H2 2015 8

Number of Products under Development by Companies, H2 2015 9

Number of Products under Investigation by Universities/Institutes, H2 2015 10

Comparative Analysis by Late Stage Development, H2 2015 11

Comparative Analysis by Clinical Stage Development, H2 2015 12

Comparative Analysis by Early Stage Development, H2 2015 13

Products under Development by Companies, H2 2015 14

Products under Investigation by Universities/Institutes, H2 2015 15

Bacterial Vaginosis-Pipeline by Alfa Wassermann S.p.A, H2 2015 16

Bacterial Vaginosis-Pipeline by AmVac AG, H2 2015 17

Bacterial Vaginosis-Pipeline by Osel Inc., H2 2015 18

Bacterial Vaginosis-Pipeline by Starpharma Holdings Limited, H2 2015 19

Bacterial Vaginosis-Pipeline by Symbiomix Therapeutics, LLC, H2 2015 20

Assessment by Monotherapy Products, H2 2015 21

Number of Products by Stage and Target, H2 2015 22

Number of Products by Stage and Mechanism of Action, H2 2015 23

Number of Products by Stage and Route of Administration, H2 2015 25

Number of Products by Stage and Molecule Type, H2 2015 27

Bacterial Vaginosis Therapeutics-Recent Pipeline Updates, H2 2015 38

Bacterial Vaginosis-Dormant Projects, H2 2015 45

Bacterial Vaginosis-Discontinued Products, H2 2015 46

List of Figures

Number of Products under Development for Bacterial Vaginosis, H2 2015 7

Number of Products under Development for Bacterial Vaginosis-Comparative Analysis, H2 2015 8

Number of Products under Development by Companies, H2 2015 9

Comparative Analysis by Early Stage Products, H2 2015 13

Assessment by Monotherapy Products, H2 2015 21

Number of Products by Top 10 Routes of Administration, H2 2015 24

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 24

Number of Products by Top 10 Molecule Types, H2 2015 26

Number of Products by Stage and Top 10 Molecule Types, H2 2015 26

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Alfa Wassermann S.p.A

AmVac AG

Osel Inc.

Starpharma Holdings Limited

Symbiomix Therapeutics, LLC

Bacterial Vaginosis Therapeutic Products under Development, Key Players in Bacterial Vaginosis Therapeutics, Bacterial Vaginosis Pipeline Overview, Bacterial Vaginosis Pipeline, Bacterial Vaginosis Pipeline Assessment

select a license

Single User License
USD 2000 INR 136780
Site License
USD 4000 INR 273560
Corporate User License
USD 6000 INR 410340



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]